KR101840079B1 - 폴리설페이트화된 폴리사카라이드에 의한 골수 부종(수종)의 치료 - Google Patents
폴리설페이트화된 폴리사카라이드에 의한 골수 부종(수종)의 치료 Download PDFInfo
- Publication number
- KR101840079B1 KR101840079B1 KR1020137022985A KR20137022985A KR101840079B1 KR 101840079 B1 KR101840079 B1 KR 101840079B1 KR 1020137022985 A KR1020137022985 A KR 1020137022985A KR 20137022985 A KR20137022985 A KR 20137022985A KR 101840079 B1 KR101840079 B1 KR 101840079B1
- Authority
- KR
- South Korea
- Prior art keywords
- polysulfate
- treatment
- bone marrow
- pps
- bme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010051763 Bone marrow oedema Diseases 0.000 title claims abstract description 59
- 150000004676 glycans Chemical class 0.000 title claims abstract description 42
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 42
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 206010030113 Oedema Diseases 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 26
- 229940043138 pentosan polysulfate Drugs 0.000 claims description 61
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 15
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 238000007918 intramuscular administration Methods 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 238000011285 therapeutic regimen Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- RWSZDLPYUAAMDO-UHFFFAOYSA-N pentanoic acid;sodium Chemical group [Na].CCCCC(O)=O RWSZDLPYUAAMDO-UHFFFAOYSA-N 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 abstract description 13
- 238000002595 magnetic resonance imaging Methods 0.000 description 32
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 30
- 208000002193 Pain Diseases 0.000 description 27
- 230000003902 lesion Effects 0.000 description 19
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 18
- 229960002897 heparin Drugs 0.000 description 18
- 229920000669 heparin Polymers 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 150000002972 pentoses Chemical class 0.000 description 16
- 210000000988 bone and bone Anatomy 0.000 description 15
- 229920001661 Chitosan Polymers 0.000 description 14
- 229920002567 Chondroitin Polymers 0.000 description 13
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 12
- 239000003055 low molecular weight heparin Substances 0.000 description 12
- 229940127215 low-molecular weight heparin Drugs 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- NBTMNFYXJYCQHQ-UHFFFAOYSA-N (2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate Chemical compound OS(=O)(=O)OC1C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C1OS(O)(=O)=O NBTMNFYXJYCQHQ-UHFFFAOYSA-N 0.000 description 6
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 6
- 229920000045 Dermatan sulfate Polymers 0.000 description 6
- 239000003708 ampul Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 229960000633 dextran sulfate Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 210000005065 subchondral bone plate Anatomy 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 208000017234 Bone cyst Diseases 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- -1 but not limited to Chemical class 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 210000003689 pubic bone Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010064269 Bone marrow oedema syndrome Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004439 collateral ligament Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010066251 Bone contusion Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000010256 bone deposition Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Polymers CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- LHYPLJGBYPAQAK-UHFFFAOYSA-M sodium;pentanoate Chemical compound [Na+].CCCCC([O-])=O LHYPLJGBYPAQAK-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011900325 | 2011-02-02 | ||
| AU2011900325A AU2011900325A0 (en) | 2011-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides | |
| PCT/AU2012/000091 WO2012103588A1 (en) | 2011-02-02 | 2012-02-02 | Treatment of bone marrow edema (oedema) with polysulfated polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140012655A KR20140012655A (ko) | 2014-02-03 |
| KR101840079B1 true KR101840079B1 (ko) | 2018-03-19 |
Family
ID=46602012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137022985A Active KR101840079B1 (ko) | 2011-02-02 | 2012-02-02 | 폴리설페이트화된 폴리사카라이드에 의한 골수 부종(수종)의 치료 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9101650B2 (enExample) |
| EP (1) | EP2670412B1 (enExample) |
| JP (1) | JP5883458B2 (enExample) |
| KR (1) | KR101840079B1 (enExample) |
| CN (1) | CN103415293B (enExample) |
| AU (1) | AU2012212398B2 (enExample) |
| CA (1) | CA2826166C (enExample) |
| DK (1) | DK2670412T3 (enExample) |
| ES (1) | ES2664611T3 (enExample) |
| MY (1) | MY164728A (enExample) |
| NO (1) | NO2670412T3 (enExample) |
| PT (1) | PT2670412T (enExample) |
| SG (1) | SG192238A1 (enExample) |
| TW (1) | TWI520740B (enExample) |
| WO (1) | WO2012103588A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6444399B2 (ja) * | 2013-10-22 | 2018-12-26 | セル レセプター アーゲー | 癌の処置に用いるための硫酸化多糖 |
| CA3071585A1 (en) | 2017-08-04 | 2019-02-07 | Paradigm Biopharmaceuticals Ltd | Treatment of bone marrow pathologies with polysulfated polysaccharides |
| CA3089077A1 (en) | 2018-02-16 | 2019-08-22 | Proteobioactives Pty Limited | Methods and compositions for the treatment of pain and/or inflammation |
| CA3091632C (en) * | 2018-02-28 | 2025-05-20 | Paradigm Biopharmaceuticals Ltd | TREATMENT OF POSTOPERATIVE JOINT PAIN WITH POLYSACCHARIDES POLYSULFATES |
| CN112888442A (zh) | 2018-10-10 | 2021-06-01 | 帕拉迪生物制药有限公司 | 多硫酸化多糖治疗疼痛 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002041901A1 (en) | 2000-11-21 | 2002-05-30 | Arthropharm Pty Ltd | Treatment of osteoporosis |
| WO2009070842A1 (en) | 2007-12-04 | 2009-06-11 | Proteobioactives Pty Ltd | Protection of progenitor cells and regulation of their differentiation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| US6564083B2 (en) * | 2000-12-18 | 2003-05-13 | Hoffmann-La Roche Inc. | Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis |
| DE10225551A1 (de) * | 2002-06-06 | 2003-12-24 | Schering Ag | Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind |
-
2012
- 2012-02-01 TW TW101103252A patent/TWI520740B/zh active
- 2012-02-02 EP EP12741560.2A patent/EP2670412B1/en active Active
- 2012-02-02 MY MYPI2013701355A patent/MY164728A/en unknown
- 2012-02-02 SG SG2013058268A patent/SG192238A1/en unknown
- 2012-02-02 CN CN201280007433.9A patent/CN103415293B/zh active Active
- 2012-02-02 US US13/983,406 patent/US9101650B2/en active Active
- 2012-02-02 NO NO12741560A patent/NO2670412T3/no unknown
- 2012-02-02 ES ES12741560.2T patent/ES2664611T3/es active Active
- 2012-02-02 CA CA2826166A patent/CA2826166C/en active Active
- 2012-02-02 WO PCT/AU2012/000091 patent/WO2012103588A1/en not_active Ceased
- 2012-02-02 DK DK12741560.2T patent/DK2670412T3/en active
- 2012-02-02 PT PT127415602T patent/PT2670412T/pt unknown
- 2012-02-02 AU AU2012212398A patent/AU2012212398B2/en active Active
- 2012-02-02 JP JP2013552065A patent/JP5883458B2/ja active Active
- 2012-02-02 KR KR1020137022985A patent/KR101840079B1/ko active Active
-
2015
- 2015-07-02 US US14/790,476 patent/US9861657B2/en active Active
-
2017
- 2017-09-29 US US15/720,884 patent/US10610542B2/en active Active
-
2020
- 2020-02-25 US US16/800,245 patent/US11406660B2/en active Active
-
2022
- 2022-07-05 US US17/857,420 patent/US20220362284A1/en not_active Abandoned
-
2023
- 2023-11-21 US US18/515,823 patent/US20240156858A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002041901A1 (en) | 2000-11-21 | 2002-05-30 | Arthropharm Pty Ltd | Treatment of osteoporosis |
| WO2009070842A1 (en) | 2007-12-04 | 2009-06-11 | Proteobioactives Pty Ltd | Protection of progenitor cells and regulation of their differentiation |
Non-Patent Citations (1)
| Title |
|---|
| Current Therapeutic Research. 2005. Vol.66, No.6, pp.552-571. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220362284A1 (en) | 2022-11-17 |
| US9861657B2 (en) | 2018-01-09 |
| TW201309307A (zh) | 2013-03-01 |
| NO2670412T3 (enExample) | 2018-06-02 |
| US20140024614A1 (en) | 2014-01-23 |
| CA2826166C (en) | 2017-05-09 |
| CN103415293A (zh) | 2013-11-27 |
| US20240156858A1 (en) | 2024-05-16 |
| US9101650B2 (en) | 2015-08-11 |
| AU2012212398A1 (en) | 2013-09-19 |
| EP2670412B1 (en) | 2018-01-03 |
| EP2670412A4 (en) | 2015-07-08 |
| KR20140012655A (ko) | 2014-02-03 |
| US10610542B2 (en) | 2020-04-07 |
| CN103415293B (zh) | 2016-08-10 |
| PT2670412T (pt) | 2018-03-20 |
| DK2670412T3 (en) | 2018-03-12 |
| US20180021369A1 (en) | 2018-01-25 |
| MY164728A (en) | 2018-01-30 |
| AU2012212398B2 (en) | 2014-06-05 |
| US11406660B2 (en) | 2022-08-09 |
| JP5883458B2 (ja) | 2016-03-15 |
| WO2012103588A1 (en) | 2012-08-09 |
| US20210015849A1 (en) | 2021-01-21 |
| SG192238A1 (en) | 2013-09-30 |
| EP2670412A1 (en) | 2013-12-11 |
| JP2014504613A (ja) | 2014-02-24 |
| TWI520740B (zh) | 2016-02-11 |
| US20150297633A1 (en) | 2015-10-22 |
| ES2664611T3 (es) | 2018-04-20 |
| CA2826166A1 (en) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240156858A1 (en) | Treatment of Bone Marrow Edema (Oedema) With Polysulfated Polysaccharides | |
| Edelson et al. | Short-Term Effects of Knee Washout for Osteoarth ritis | |
| van Roermund et al. | Joint distraction in the treatment of ankle osteoarthritis | |
| Barakat et al. | Prevention of post-traumatic osteoarthritis after intra-articular knee fractures using hyaluronic acid: a randomized prospective pilot study | |
| Afzal et al. | Study to determine the efficacy of illizarov fixator for the treatment of complex tibial plateau fractures | |
| Barner et al. | Simultaneous bilateral rupture of patellar tendons in a young man without predisposing factors or systemic disease | |
| Specchiulli et al. | Peritalar dislocations | |
| Manjunath et al. | A prospective study of surgical management of bicondylar schatzker type V & VI tibial plateau fracture by dual plating and dual incision | |
| Saluta et al. | Managing foot and ankle injuries in athletes | |
| Gu et al. | Effect of internal fixation of tibial fracture with suprapatellar approach and subpatellar approach on fracture union and knee function recovery | |
| Street et al. | Atraumatic medullary osteonecrosis of the tibia and femur treated with intraosseous orthobiologics | |
| de Ávila | Literature review of biomechanics of the ankle/foot complex: changes in functional activities postoperatively for ankle fractures | |
| Zhang et al. | Single-incision Non-weight-bearing Area Autologous Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus | |
| Soni | Functional Outcome in Management of Open Tibial Diaphyseal Fractures by Limb Reconstruction System as Primary and Definitive Tool-A Prospective Study | |
| Adukia et al. | Journal of Arthroscopy and Joint Surgery | |
| Sheeraz | Prevention and Postoperative Care | |
| Murrell | WD Murrell | |
| Puri | Clinical study on the management of complex metaphyseal fractures of the tibia (proximal and distal) with hybrid external fixation | |
| Montaser | Arthroscopic treatment of traumatic anterior bony ankle impingement | |
| Stapp | Joel V. Ferreira, Vinayak M. Sathe, Michael Aronow, and | |
| JP2021514988A (ja) | ポリ硫酸化多糖類を用いた術後関節痛の処置 | |
| Rosario Saccomanno et al. | Monthly Archives: December 2020 | |
| Shamsi et al. | Yearly Archives: 2012 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130830 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20161229 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170920 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180227 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180313 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20180313 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20210302 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220302 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230130 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240110 Start annual number: 7 End annual number: 7 |